- Home
- UTHR vs MKL Comparison
UTHR vs MKL Comparison
Compare UTHR & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- MKL
- Stock Information
- Founded
- UTHR 1996
- MKL 1930
- Country
- UTHR United States
- MKL United States
- Employees
- UTHR N/A
- MKL N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- MKL Property-Casualty Insurers
- Sector
- UTHR Health Care
- MKL Finance
- Exchange
- UTHR Nasdaq
- MKL Nasdaq
- Market Cap
- UTHR 20.7B
- MKL 24.4B
- IPO Year
- UTHR 1999
- MKL 1986
- Fundamental
- Price
- UTHR $453.53
- MKL $1,938.38
- Analyst Decision
- UTHR Buy
- MKL Hold
- Analyst Count
- UTHR 14
- MKL 2
- Target Price
- UTHR $471.50
- MKL $1,930.50
- AVG Volume (30 Days)
- UTHR 658.6K
- MKL 37.3K
- Earning Date
- UTHR 10-29-2025
- MKL 10-29-2025
- Dividend Yield
- UTHR N/A
- MKL N/A
- EPS Growth
- UTHR 16.08
- MKL N/A
- EPS
- UTHR 26.38
- MKL 157.62
- Revenue
- UTHR $3,128,400,000.00
- MKL $16,210,307,000.00
- Revenue This Year
- UTHR $13.82
- MKL N/A
- Revenue Next Year
- UTHR $5.71
- MKL $1.35
- P/E Ratio
- UTHR $17.26
- MKL $11.59
- Revenue Growth
- UTHR 13.50
- MKL N/A
- 52 Week Low
- UTHR $266.98
- MKL $1,521.25
- 52 Week High
- UTHR $479.50
- MKL $2,075.92
- Technical
- Relative Strength Index (RSI)
- UTHR 62.66
- MKL 50.17
- Support Level
- UTHR $409.15
- MKL $1,812.24
- Resistance Level
- UTHR $479.50
- MKL $1,904.41
- Average True Range (ATR)
- UTHR 13.12
- MKL 29.00
- MACD
- UTHR -1.19
- MKL -3.99
- Stochastic Oscillator
- UTHR 57.20
- MKL 60.12
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.